ロード中...

Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN

BACKGROUND: We assessed the safety profile of lasmiditan, a selective 5-HT(1F) receptor agonist without vasoconstrictive activity being developed as an acute therapy for migraine. METHODS: SAMURAI and SPARTAN were Phase 3 double-blind studies of patients with migraine, randomized to oral lasmiditan...

詳細記述

保存先:
書誌詳細
出版年:Cephalalgia
主要な著者: Krege, John H, Rizzoli, Paul B, Liffick, Emily, Doty, Erin G, Dowsett, Sherie A, Wang, Jianing, Buchanan, Andrew S
フォーマット: Artigo
言語:Inglês
出版事項: SAGE Publications 2019
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6787764/
https://ncbi.nlm.nih.gov/pubmed/31166697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0333102419855080
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!